Growing community of inventors

Chestnut Hill, MA, United States of America

Paul M Ridker

Average Co-Inventor Count = 1.88

ph-index = 4

The patent ph-index is calculated by counting the number of publications for which an author has been cited by other authors at least that same number of times.

Forward Citations = 151

Paul M RidkerDov Shiffman (3 patents)Paul M RidkerCharles H Hennekens (3 patents)Paul M RidkerDaniel Chasman (3 patents)Paul M RidkerPeter Libby (1 patent)Paul M RidkerJoAnn E Manson (1 patent)Paul M RidkerUwe Schönbeck (1 patent)Paul M RidkerPaul M Ridker (10 patents)Dov ShiffmanDov Shiffman (12 patents)Charles H HennekensCharles H Hennekens (4 patents)Daniel ChasmanDaniel Chasman (3 patents)Peter LibbyPeter Libby (3 patents)JoAnn E MansonJoAnn E Manson (2 patents)Uwe SchönbeckUwe Schönbeck (1 patent)
..
Inventor’s number of patents
..
Strength of working relationships

Company Filing History:

1. The Brigham and Women's Hospital, Inc. (10 from 1,371 patents)

2. Celera Corporation (2 from 98 patents)

3. Applera Corporation (1 from 496 patents)


10 patents:

1. 11697850 - Polymorphism in the Apo(a) gene predict responsiveness to acetylsalicylic acid treatment

2. 11435363 - Relevance of achieved levels of markers of systemic inflammation following treatment

3. 10550433 - Polymorphism in the Apo(a) gene predict responsiveness to acetylsalicylic acid treatment

4. 9164104 - Relevance of achieved levels of markers of systemic inflammation following treatment

5. 8101363 - Inflammatory markers as tools in the detection and prevention of diabetes mellitus and as tools to aid in the selection of agents to be used for the prevention and treatment of diabetes

6. 7964614 - Systemic inflammatory markers as diagnostic tools in the prevention of atherosclerotic diseases and as tools to aid in the selection of agents to be used for the prevention and treatment of atherosclerotic disease

7. 7943317 - Polymorphism in the Apo(a) gene predict responsiveness to acetylsalicylic acid treatment

8. 7189518 - Soluble CD40L(CD154) as a prognostic marker of atherosclerotic diseases

9. 7030152 - Systematic inflammatory markers as diagnostic tools in the prevention of atherosclerotic diseases and as tools to aid in the selection of agents to be used for the prevention and treatment of atherosclerotic disease

10. 6040147 - Systemic inflammatory markers as diagnostic tools in the prevention of

Please report any incorrect information to support@idiyas.com
idiyas.com
as of
12/15/2025
Loading…